文献速递炎症性肠病

联合治疗在克罗恩病中的益处取决于疾病表型和病程

The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2017-05-03

该多中心前瞻性队列纳入707例克罗恩病和164例溃疡性结肠炎患者,比较抗TNF单药与联合免疫调节剂治疗。联合治疗在总体克罗恩病和溃疡性结肠炎中未显著降低1年复合不良结局,但在狭窄型或穿透型克罗恩病及病程<5年者中观察到显著获益,且英夫利西单抗与其他抗TNF生物制剂效果相似。

要点

  • 联合治疗在总体克罗恩病(OR 0.87,95%CI 0.63-1.22)和溃疡性结肠炎(OR 1.45,95%CI 0.63-3.38)中未显著降低1年复合结局。
  • 狭窄型或穿透型克罗恩病患者联合治疗组结局发生率为30%,低于未联合组的39%(OR 0.58,95%CI 0.37-0.90)。
  • 病程<5年的克罗恩病患者联合治疗OR为0.35(95%CI 0.14-0.87),优于病程较长者的OR 0.75(95%CI 0.45-1.27)。

核心结论

  • 联合免疫调节剂-生物制剂治疗的益处在复杂型克罗恩病中更强,尤其是在疾病早期。

研究设计与样本

  • 多中心前瞻性队列研究,纳入707例克罗恩病患者(45%接受联合治疗)和164例溃疡性结肠炎患者(38%接受联合治疗)。
  • 将患者分为抗TNF单药治疗组和联合免疫调节剂治疗组,主要结局为1年内新发IBD相关手术、住院、穿透性并发症、需要使用糖皮质激素或新生物制剂的复合结局。
  • 采用多变量回归模型校正潜在混杂因素。

主要发现

  • 联合治疗与克罗恩病复合结局降低无关(OR 0.87,95%CI 0.63-1.22),与溃疡性结肠炎复合结局降低也无关(OR 1.45,95%CI 0.63-3.38)。
  • 在非狭窄非穿透型克罗恩病患者中未见差异,而在狭窄型或穿透型克罗恩病患者中,联合治疗组结局发生率为30%,未联合组为39%(OR 0.58,95%CI 0.37-0.90)。
  • 病程<5年的克罗恩病患者联合治疗OR为0.35(95%CI 0.14-0.87),病程较长者OR为0.75(95%CI 0.45-1.27)。
  • 英夫利西单抗与其他抗TNF生物制剂在复合结局发生率上观察到相似的降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of combination therapy on disease-related morbidity in patients with established Crohn's disease (CD) or ulcerative colitis (UC) remains to be well-defined. AIM: To examine the effect of combination therapy on disease outcomes in CD and UC. METHODS: Using a multicenter prospective cohort, we classified CD and UC patients as being on monotherapy with anti-TNF or on combination with an immunomodulator. The primary outcome was a composite of new IBD-related surgery, hospitalisations, penetrating complications, need for corticosteroids or new biological at 1 year. Multivariable regression models adjusted for potential confounders. RESULTS: We included 707 patients with CD (45% combination therapy) and 164 with UC (38% combination therapy). Combination therapy was not associated with reduction in the composite outcome in either CD (OR: 0.87, 95% CI: 0.63-1.22) or UC (OR: 1.45, 95% CI: 0.63-3.38). However, while no difference was noted in those with nonstricturing, nonpenetrating CD, a significant reduction in the likelihood of the outcome was seen in those with stricturing or penetrating CD (30% vs 39%, OR: 0.58, 95% CI: 0.37-0.90). A stronger effect was also observed in those with disease duration <5 years (OR: 0.35, 95% CI: 0.14-0.87) compared to those with a longer duration (OR: 0.75, 95% CI: 0.45-1.27). A similar reduction in occurrence of composite outcome was noted with infliximab and with other anti-TNF biologics. CONCLUSION: The benefit of combination immunomodulator-biological therapy is stronger in those with complicated Crohn's disease, particularly early on in their disease course.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ananthakrishnan AN, Sakuraba A, Barnes EL, et al. The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther. 2017. PMID: 28470787. doi:10.1111/apt.14125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。